Safety of incremental inhaled lipopolysaccharide challenge in humans

Abstract

Background: Inhalation of environmental endotoxin is important in the pathogenesis of asthma and other environmental airway diseases. Inhaled airway challenge using lipopolysaccharide in humans has been performed for over 20 years to assess the airway response to endotoxin. However, there are no published data on the short-term safety of endotoxin inhalation protocols.

Objective: To characterize the safety and tolerability of incremental inhaled lipopolysaccharide challenge in humans.

Patients and Methods : We performed a retrospective analysis of data obtained from 119 subjects who underwent inhaled challenge with up to 41.5 µg of lipopolysaccharide. We measured pulmonary function, temperature, mean arterial pressure, heart rate, and systemic symptoms for 3 h after challenge. Results: Fever occurred in 30% of subjects and was associated with a higher cumulative dose of lipopolysaccharide. Reduced mean arterial pressure occurred in 21% of subjects and was dose-related. There was no association between fever or decreased mean arterial pressure and airway responsiveness to inhaled lipopolysaccharide. Common symptoms reported by subjects included: chills (64%), malaise (56%), cough (56%), chest tightness (49%), headache (43%), and myalgias (27%). None of the subjects experienced delayed discharge or a serious adverse event.

Conclusions: Inhaled lipopolysaccharide causes dose-related systemic responses that include fever, reduced blood pressure, and constitutional symptoms that are not associated with the airway response to inhaled lipopolysaccharide. Systemic responses to inhaled lipopolysaccharide should be expected and subjects undergoing inhaled lipopolysaccharide challenge in the research setting should be carefully monitored for non-pulmonary adverse events for several hours after challenge.

Keywords

Lipopolysaccharide endotoxin inhalation challenge systemic responses

References

Bonner JC , Rice AB , Lindroos PM et al. Induction of the lung myofibroblast PDGF receptor system by urban ambient particles from Mexico City. Am J Respir Cell Mol Biol 1998; 19: 672—680.

Suffredini AF , Hochstein HD , McMahon FG Dose-related inflammatory effects of intravenous endotoxin in humans: evaluation of a new clinical lot of Escherichia coli O:113 endotoxin. J Infect Dis 1999; 179: 1278—1282.

Rylander R. , Bake B. , Fischer JJ , Helander IM Pulmonary function and symptoms after inhalation of endotoxin. Am Rev Respir Dis 1989; 140: 981—986.

Rylander R. , Haglind P. , Lundholm M. Endotoxin in cotton dust and respiratory function decrement among cotton workers in an experimental cardroom. Am Rev Respir Dis 1985; 131: 209—213.

Michel O. , Ginanni R. , Le Bon B. , Content J. , Duchateau J. , Sergysels R. Inflammatory response to acute inhalation of endotoxin in asthmatic patients . Am Rev Respir Dis 1992; 146: 352—357.

Gehring U. , Bischof W. , Fahlbusch B. , Wichmann HE , Heinrich J. House dust endotoxin and allergic sensitization in children. Am J Respir Crit Care Med 2002; 166: 939—944.

Braun-Fahrlander C. , Riedler J. , Herz U. et al. Environmental exposure to endotoxin and its relation to asthma in school-age children. N Engl J Med 2002; 347: 869—877.

Michel O. , Ginanni R. , Duchateau J. , Vertongen F. , Le Bon B. , Sergysels R. Domestic endotoxin exposure and clinical severity of asthma. Clin Exp Allergy 1991; 21: 441—448.

Michel O. , Kips J. , Duchateau J. et al. Severity of asthma is related to endotoxin in house dust. Am J Respir Crit Care Med 1996; 154: 1641—1646.

10.

Kline JN , Cowden JD , Hunninghake GW et al. Variable airway responsiveness to inhaled lipopolysaccharide . Am J Respir Crit Care Med 1999; 160: 297—303.

11.

Clapp WD , Thorne PS , Frees KL , Zhang X. , Lux CR , Schwartz DA The effects of inhalation of grain dust extract and endotoxin on upper and lower airways. Chest 1993; 104: 825—830.

12.

Arbour NC , Lorenz E. , Schutte BC et al. TLR4 mutations are associated with endotoxin hyporesponsiveness in humans. Nat Genet 2000; 25: 187—191.

13.

Van der Zwan JC , Orie NG , Kauffman HF , Wiers PW , de Vries K. Bronchial obstructive reactions after inhalation with endotoxin and precipitinogens of Haemophilus influenzae in patients with chronic non-specific lung disease. Clin Allergy 1982; 12: 547—559.

14.

Michel O. , Dentener M. , Corazza F. , Buurman W. , Rylander R. Healthy subjects express differences in clinical responses to inhaled lipopolysaccharide that are related with inflammation and with atopy. J Allergy Clin Immunol 2001; 107: 797—804.

15.

Alexis NE , Eldridge MW , Peden DB Effect of inhaled endotoxin on airway and circulating inflammatory cell phagocytosis and CD11b expression in atopic asthmatic subjects. J Allergy Clin Immunol 2003; 112: 353—361.

16.

Thorn J. , Rylander R. Inflammatory response after inhalation of bacterial endotoxin assessed by the induced sputum technique. Thorax 1998; 53: 1047—1052.

17.

Michel O. , LeVan TD , Stern D. et al. Systemic responsiveness to lipopolysaccharide and polymorphisms in the Toll-like receptor 4 gene in human beings. J Allergy Clin Immunol 2003; 112: 923—929.

18.

Jamison JP , Lowry RC Bronchial challenge of normal subjects with the endotoxin of Enterobacter agglomerans isolated from cotton dust. Br J Ind Med 1986; 43: 327—331.

19.

Michel O. , Duchateau J. , Sergysels R. Effect of inhaled endotoxin on bronchial reactivity in asthmatic and normal subjects. J Appl Physiol 1989; 66: 1059—1064.

20.

Michel O. , Ginanni R. , Sergysels R. Relation between the bronchial obstructive response to inhaled lipopolysaccharide and bronchial responsiveness to histamine. Thorax 1992; 47: 288—291.

21.

Herbert A. , Carvalheiro M. , Rubenowitz E. , Bake B. , Rylander R. Reduction of alveolar-capillary diffusion after inhalation of endotoxin in normal subjects. Chest 1992; 102: 1095—1098.

22.

Sandstrom T. , Bjermer L. , Rylander R. Lipopolysaccharide (LPS) inhalation in healthy subjects increases neutrophils, lymphocytes and fibronectin levels in bronchoalveolar lavage fluid. Eur Respir J 1992; 5: 992—996.

23.

Michel O. , Ginanni R. , Sergysels R. Protective effect of sodium cromoglycate on lipopolysaccharide-induced bronchial obstruction in asthmatics. Int Arch Allergy Immunol 1995; 108: 298—302.

24.

Michel O. ,. Duchateau J. , Plat G. et al. Blood inflammatory response to inhaled endotoxin in normal subjects . Clin Exp Allergy 1995; 25: 73—79.

25.

Jagielo PJ , Thorne PS , Watt JL , Frees KL , Quinn TJ , Schwartz DA Grain dust and endotoxin inhalation challenges produce similar inflammatory responses in normal subjects. Chest 1996; 110: 263—270.

26.

Rolla G. , Bucca C. , Brussino L. , Dutto L. , Colagrande P. , Polizzi S. Pentoxifylline attenuates LPS-induced bronchial hyperresponsiveness but not the increase in exhaled nitric oxide. Clin Exp Allergy 1997; 27: 96—103.

27.

Michel O. , Nagy AM , Schroeven M. et al. Dose-response relationship to inhaled endotoxin in normal subjects . Am J Respir Crit Care Med 1997; 156: 1157—1164.

28.

Wesselius LJ , Nelson ME , Bailey K. , O'Brien-Ladner AR. Rapid lung cytokine accumulation and neutrophil recruitment after lipopolysaccharide inhalation by cigarette smokers and nonsmokers. J Lab Clin Med 1997 ; 129: 106—114.

29.

Michel O. , Olbrecht J. , Moulard D. , Sergysels R. Effect of antiasthmatic drugs on the response to inhaled endotoxin. Ann Allergy Asthma Immunol 2000; 85: 305—310.

30.

Von Essen S , Fryzek J. , Nowakowski B. , Wampler M. Respiratory symptoms and farming practices in farmers associated with an acute febrile illness after organic dust exposure . Chest 1999; 116: 1452—1458.

31.

van Eeden SF , Hogg JC Systemic inflammatory response induced by particulate matter air pollution: the importance of bone-marrow stimulation . J Toxicol Environ Health A 2002; 65: 1597—1613.